New Gene & Cell Therapy Approval Announced

 
The US Food and Drug Administration (FDA) has granted expanded approval to Bristol Myers Squibb K.K. for its therapy, Abecma® (idecabtagene vicleucel), for the treatment of Multiple Myeloma, making it available in earlier lines of treatment. 

PartnerRe’s team of dedicated clinical consultants are here to help you navigate the ever-changing healthcare market and manage your risk through integrated medical management solutions that optimize clinical and financial outcomes. We work with you to limit and prohibit high-cost mark-ups on new life enhancing Gene & Cell Therapies. 

We are here for you and look forward to answering your questions or sharing news on this approval as more information becomes available.

Contact us to find our more, and learn how our gene and cell therapy program can work for you: partnerrehealth@partnerre.com
 
Drug Category
Cell Therapy
Drug Name
Abecma® (idecabtagene vicleucel)
FDA Approval Date
4/5/2024
Anticipated Cost
$498,408
Medical Condition
Multiple Myeloma
FDA Approval Indication
Treatment of adult patients with relapsed or refractory (r/r) multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.  
US Incidence &
US Prevalence
According to the American Cancer Society the lifetime risk for a person to get multiple myeloma is one in 132 (0.76 percent). The estimated number of new cases in 2022 in the U.S. is 34,470 (19,100 in men and 15,370 in women). Deaths expected to occur are 12,640 (7,090 in men and 5,550 in women). Multiple myeloma is more common in men than women and among individuals who are non-Hispanic Black.

The median age of onset is 68 years. Only 18 percent of individuals diagnosed with multiple myeloma are under the age of 50 years
Key Considerations
  • Inpatient
  • Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy (bms.com)
ICD-10 Codes
C90.00-C90.02
C90.10-C90.12
C90.20-C90.22
C90.30-C90.32
J Codes
Q2055
For full label information and more, visit CAR T Cell Therapy for R/R Multiple Myeloma | ABECMA® (idecabtagene vicleucel)

Our PULSE + Plus® Clinical Consultants are here to help you navigate the process and answer your questions about all things gene and cell therapy related. Our commitment is to provide you offerings that deliver the best clinical and financial outcome, while delivering ongoing support every step of the way.


 

PartnerRe Health is a division of PartnerRe Ltd. In the US, coverage is underwritten by PartnerRe America Insurance Company. This literature is descriptive only. Actual coverage is subject to the language of the policies or agreements as issued. There are references throughout this document to various trademarks or service marks and these, whether registered or not, are the property of their respective owners. The registered marks “PartnerRe” and “PULSE + Plus® marks are owned by PartnerRe Ltd. PartnerRe America Insurance Company (PartnerRe) is not a direct provider of case management or utilization review services. Any such services are provided through Specialty Service Providers with whom PartnerRe arranges direct contracts for its clients.

partnerre.com

© 2023 PartnerRe

PartnerRe Business Privacy Notice

Salesforce/Pardot Privacy Policy

FDAAND0123